Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Mikhail KorogluyevM.D.,D.O.
Osteopathic Manipulative Medicine · Brooklyn, NY 11235
NPI: 1083820252
43
🟠 Elevated
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
31,724
Total Claims
$13.2M
Drug Cost
479
Beneficiaries
$28K
Cost/Patient
Risk Score Breakdown 43/100
Score components are additive. Read full methodology
Peer Comparison vs. 516 Osteopathic Manipulative Medicine providers
-89%
Opioid rate vs peers
0.8% vs 7.5% avg
+2400%
Cost per patient vs peers
$28K vs $1,104 avg
+495%
Brand preference vs peers
44.1% vs 7.4% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Cost per patient is 2400% above the specialty average. Extreme cost outliers may indicate prescribing of unnecessarily expensive brand-name drugs or inappropriate drug utilization.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
0.8%
Opioid Rate
249
Opioid Claims
$9,670
Opioid Cost
13.3%
Long-Acting Rate
Brand vs Generic
Brand: 13,778 claims · $11.9M
Generic: 17,437 claims · $1.3M
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Diclofenac Sodium | 678 | $1.8M |
| Lipase/Protease/Amylase | 653 | $1.5M |
| Lipase/Protease/Amylase | 471 | $975K |
| Linaclotide | 1,288 | $730K |
| Icosapent Ethyl | 1,275 | $501K |
| Dihydroergotamine Mesylate | 256 | $473K |
| Dulaglutide | 379 | $410K |
| Semaglutide | 338 | $346K |
| Cyclosporine | 483 | $337K |
| Mirabegron | 682 | $337K |
| Dapagliflozin Propanediol | 405 | $251K |
| Diclofenac Sodium | 292 | $231K |
| Efinaconazole | 142 | $225K |
| Apixaban | 346 | $220K |
| Omeprazole/Sodium Bicarbonate | 103 | $209K |
Prescribing Profile
Patient Profile
73
Avg Age
64%
Female
1.49
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About